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ABSTRACT 
A simple, sensitive and accurate UV spectrophotometric method has been developed  for the determination of Gemfibrozil in bulk and 
pharmaceutical  tablet  dosage  formulation.  This method  obeys  Beer’s  law  in  the  concentration  range  of  30-90  µg/ml.  with  correlation 
coefficient of 0.9993 and exhibiting maximum absorption at 276 nm with apparent molar absorptivity of 0.1703 × 10
4 L mole
-1 cm
-1. The 
method is accurate and precise and is extended to pharmaceutical tablet dosage forms and there was no interference from any common 
pharmaceutical additives and excipients. The results of analysis were validated statistically and by recovery studies. 
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INTRODUCTION  
Absorption  spectroscopy  is  one  of  the  most  valuable 
analytical techniques; its advantages include simplicity, 
speed, specificity and sensitivity
1. Gemfibrozil (GEM) is 
5-(2,  5-dimethylphenoxy)-2,  2-dimethylpentanoic  acid. 
The  drug  is  used  for  the  treatment  of  hyperlipidemia. 
Gemfibrozil is a lipid regulating agent which decreases 
serum  triglycerides  and  very  low  density  lipoprotein 
(VLDL)  cholesterol,  and  increases  high  density 
lipoprotein (HDL) cholesterol. While modest decreases 
in  total  and  low  density  lipoprotein  (LDL)  cholesterol 
may be observed with drug therapy, treatment of patients 
with  elevated  triglycerides  due  to  Type  IV 
hyperlipoproteinemia  often  results  in  a  rise  in  LDL 
cholesterol. LDL-cholesterol levels in Type II-b patients 
with  elevations  of  both  serum  LDL-cholesterol  and 
triglycerides are, in general, minimally affected by drug 
treatment;  however,  Gemfibrozil  usually  raises  HDL-
cholesterol  significantly  in  this  group.  Gemfibrozil 
increases  levels of high density  lipoprotein (HDL) sub 
fractions HDL2 and HDL3, as well as apolipoproteins AI 
and  AII.    It  also  increases  activity  of  peroxisome 
proliferators-activated  receptor-alpha  (PPAR-α) 
‘transcription factor ligand’, a receptor that is involved in 
metabolism of carbohydrates and fats, as well as adipose 
tissue  differentiation.  This  increase  in  the  synthesis  of 
lipoprotein  lipase  thereby  increases  the  clearance  of 
triglycerides
2,3. A literature survey regarding quantitative 
analysis  of  drug  revealed  that  attempts  were  made  to 
develop  analytical  methods  for  Gemfibrozil  and  its 
metabolite  in  plasma  using  Gas  chromatography
4,  RP-
HPLC
5,  LC-MS
6-7  and  also  developed  method  with 
combination of Gemfibrozil and Rosiglitazone in human 
plasma  using  spectroflourimetric
8  and  RP-HPLC
9  and 
also  developed  method  for  Gemfibrozil  in 
pharmaceutical  dosage  form  using  spectroflourimetric 
method
10.  The  Aim  of  the  work  was  to  develop  an 
accurate,  specific  and  reproducible  UV-
Spectrophotometric  method  for  the  determination  of 
Gemfibrozil in dosage form. The proposed method was 
optimized and validated in accordance with International 
Conference    on    Harmonization    (ICH) guidelines. 
MATERIAL AND METHODS 
Equipment and Reagent 
Perkin  Elmer,  Lambda-19  double  beam  UV-  visible 
spectrophotometer with a matched pair of 10mm quartz 
cells  are  used  for  experimental  purpose.  Methanol 
(Merck-AR grade) is used. The commercially available 
brand  containing  Gemfibrozil  600mg  have  procured 
from local market. 
Preparation of standard stock solution 
Accurately  weighed 100  mg of Gemfibrozil pure drug 
taken in separate 100 ml. volumetric flask and dissolved 
in 70 ml of Methanol and shaken for 30 min and then 
diluted  with  methanol  up  to  100  ml  to  get  1  mg/ml. 
standard stock solution. 
Construction of calibration curve 
Aliquots of standard stock solution were pipetted out and 
suitably  diluted  with  methanol  to  get  the  final 
concentration of 30-90 µg/ml. The solution was scanned 
in the spectrum mode from 400 nm - 200 nm wavelength 
range and a sharp peak was obtained at 276 nm (Fig 2). Parikh Vikas C et al. IRJP 2 (6) 2011 106-109 
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Calibration curve (Fig 3) was constructed by plotting the 
absorbance  against  the  concentration  and  regression 
equation was computed. The results for linearity study 
were tabulated (Table 1). 
Analysis of formulation 
For the estimation of Gemfibrozil from tablets, 20 tablets 
were weighed separately and their average weight was 
calculated. Tablets were crushed separately in mortar and 
pastle  and  passed  through  fine  sieve  separately.  A 
portion of the powder equivalent to 100 mg of drug was 
accurately  weighed and transferred to separate 100  ml 
volumetric flasks. The drug was dissolved by adding 70 
ml  of  methanol  to  the  volumetric  flask  with  constant 
stirring for 15-20 min in sonicator. Volumes were made 
up  to  mark  with  methanol.  Sample  solution  of  10  ml 
transferred to 100 ml volumetric flask and diluted up to 
the  mark  with  methanol  and  diluted  the  supernatant 
sample solution to get the concentration of 30-90 µg/ml 
of Gemfibrozil. Evaluation was performed with double 
beam  spectrophotometer  for  Gemfibrozil  at  276  nm 
(Table 2). 
Validation of proposed method  
Accuracy of the method was determined by the recovery 
studies  in  the  tablets  formulations  of  the  Gemfibrozil. 
Recovery studies were carried out by addition of known 
quantities  of  standard  drug  to  pre-analyzed  sample  at 
three different concentrations. Also the experiment was 
repeated  three  times  in  a  day  to  determine  intra-day 
precision and on three different days to determine inter-
day precision. The percentage relative standard deviation 
was calculated at each concentration level. The values of 
method validation as shown in Table 3. 
RESULTS AND DISCUSSION 
Beer’s law is obeyed over the concentration range of 30-
90 µg/ml, using regression analysis the linear equation Y 
= 0.0067x - 0.0045 with correlation coefficient of R
2 = 
0.9993. The sandell’s sensitivity and molar absorptivity 
were found to be 0.1472 and 0.1703 × 10
4. The detection 
limit or LOD  is the  lowest amount of an analyte in a 
sample  that  can  be  detected,  but  not  necessarily 
quantified,  under  the  stated  experimental  conditions. 
Based on the standard deviation of the response of Y-
intercept and slope, the detection limit may be expressed 
as DL = 3.3 σ/s. The limit of detection for Gemfibrozil 
was found to be 2.5193µg/ml. Quantitation limit or LOQ 
is the  lowest amount of analyte  in sample that can  be 
determined with acceptable precision and accuracy under 
the stated experimental conditions. Based on the standard 
deviation of the response of Y-intercept and slope, the 
quantitation limit may be expressed as QL = 10 σ/S. The 
limit  of  quantitation  for  Gemfibrozil  was  found  to  be 
7.6345µg/ml.   
Method  was  validated  in  terms  of  accuracy  and 
precision.  The  accuracy  of  the  method  was  proved  by 
performing  recovery  studies  in  the  commercially 
available formulations. Values greater than 99% indicate 
that proposed method is accurate for the analysis of drug 
and there is no interference from the excipients present in 
the  formulations.  The  precision  of  the  method  was 
checked  in  terms  of  Inter-day  and  Intra-day,  where 
method  were  repeated  on  three  different  day  and  also 
repeated on  three different time periods  in same day. 
The results were given in Table 3 and shows % RSD of 
less  than  1%  at  each  level  clearly  indicate  that  the 
method is precise enough for the analysis of the drug. 
CONCLUSION 
In the above developed method, there was no additional 
extraction or separation procedure to extract the active 
ingredient  from  the  formulation.  The  errors  in 
quantification can be decreased by the elimination of this 
procedure.  Hence,  the  developed  method  is,  simple, 
accurate,  sensitive  and  economical  for  the  routine 
estimation  of  Gemfibrozil  in  bulk  drug  and  its 
pharmaceutical formulations. 
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Table 1: OPTICAL PARAMETER FOR GEMFIBROZIL 
SR.NO  Parameters  Data 
1  λ Max  276 nm 
2  Linearity  30-90 µg/ml 
3  Regression equation  Y = 0.0067x - 0.0045 
4  Correlation coefficient  R
2 = 0.9993 
5  Slope  0.0067 
6  Intercept  0.0045 
7  LOD  2.593 µg/ml 
8  LOQ  7.6345µg/ml 
9  Sandell’s sensitivity  0.1472 
10  Molar absorptivity  0.1703 × 10
4L/mole cm 
 
Table 2: RESULT OF ANALYSIS OF GEMFIBROZIL IN PHARMACEUTICAL FORMULATION 
Sr.no.  Drug  Amount found 
(mg/tab) 
% Label claim 
(%) 
S.D*  %RSD  S.E*  95%  CI 
      Lower  Upper 
1   
Gemfibrozil 
Tablets 
600mg 
598.52  99.75333   
0.2122 
 
0.2123 
 
0.0867 
 
99.77 
 
 
100.11  2  599.2  99.86667 
3  599.34  99.89 
4  598.92  99.82 
5  600.15  100.025 
6  602.05  100.3417 
*(n=6), S.D = standard Deviation, % RSD = Percentage relative Standard Deviation, S.E = Standard Error, C.I = Confidence Interval. 
 
Table 3: VALIDATION DATA FOR PROPOSED METHOD:  FOR ACCURACY 
Amt. of sample  Amt. of drug added  Amt. of drug recovered  % Recovery 
Gemfibrozil 
mg 
Gemfibrozil 
mg 
Gemfibrozil 
mg 
Gemfibrozil 
% 
30  0  -  - 
30  15  44.8  99.56 
30  30  59.1  98.50 
30  45  75.3  100.40 
 
 
Table 4: VALIDATION DATA FOR PROPOSED METHOD:  FOR PRECISION 
Conc. 
µg/ml 
Intra-day (n=3) 
Mean ± S.D. 
CV  Inter-day (n=3) 
Mean ± S.D. 
CV 
45  0.298043 ± 0.000974  0.33  0.29767 ± 0.000429  0.14 
60  0.396736 ± 0.0009166  0.23  0.396213 ± 0.000524  0.13 
75  0.497307 ± 0.001846  0.37  0.4968 ± 0.001538  0.31 
*(n=3) 
 
 
5-(2, 5-dimethylphenoxy)-2, 2-dimethylpentanoic acid 
Fig 1: chemical structure of Gemfibrozil 
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Fig 2: λ-max graph for Gemfibrozil pure drug. 
 
 
Fig 3: Calibration curve for Gemfibrozil. 
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